Malcolm Brenner

Board Director

Director

US·SEC (Form 4)

Allovir, Inc.

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

—

Latest filing published 07 Jun 2024 for Allovir, Inc.. Read the official filing

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

No signal scores available.

Malcolm Brenner: trading record in brief

This profile gathers the share dealings of Malcolm Brenner in Kalaris Therapeutics, Inc., where the filings describe the role as board member. In total, 3 filings cover trades dated from 25 May 2021 to 6 June 2024.

None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.

The newest entry dates from 7 June 2024: a share grant, in Kalaris Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.